AIM
===

The overall aim of the project was to create a clinical practice guideline with recommendations for GN, using an evidence-based approach. After topics and relevant clinical questions were identified, the pertinent scientific literature on those topics was systematically searched and summarized.

OVERVIEW OF PROCESS
===================

The development of the guideline included sequential and concurrent steps: Appoint the Work Group and Evidence Review Team (ERT), which were responsible for different aspects of the process.Confer to discuss process, methods, and results.Develop and refine topics.Assign topics to systematic review or narrative review.Define specific populations, interventions or predictors, and outcomes of interest for systematic review topics.Create and standardize quality assessment methods.Create data-extraction forms.Develop literature search strategies and run searches.Screen abstracts and retrieve full articles based on predetermined eligibility criteria.Extract data and perform critical appraisal of the literature.Incorporate existing systematic reviews and underlying studies.Grade quality of the outcomes of each study.Tabulate data from articles into summary tables.Update the systematic review search.Grade the quality of evidence for each outcome, and assess the overall quality and findings of bodies of evidence with the aid of evidence profiles.Write recommendations and supporting rationale statements.Grade the strength of the recommendations based on the quality of the evidence and other considerations.

The Work Group, KDIGO Co-Chairs, ERT, and NKF support staff met for three 3-day meetings for training in the guideline development process, topic discussion, and consensus development.

Creation of Groups
------------------

The KDIGO Co-Chairs appointed the Co-Chairs of the Work Group, who then assembled the Work Group to be responsible for the development of the guidelines. The Work Group included individuals with expertise in adult and pediatric nephrology, epidemiology, and kidney pathology. For support in evidence review, expertise in methods, and guideline development, the NKF contracted with the ERT based at the Tufts Center for Kidney Disease Guideline Development and Implementation at Tufts Medical Center in Boston, Massachusetts, USA. The ERT consisted of physician-methodologists with expertise in nephrology and internal medicine, and research associates and assistants. The ERT instructed and advised Work Group members in all steps of literature review, critical literature appraisal, and guideline development. The Work Group and the ERT collaborated closely throughout the project.

Systematic Review: General Process
----------------------------------

The first task of the Work Group was to define the overall topics and goals for the guideline. The Work Group Co-Chairs drafted a preliminary list of topics. The Work Group identified the key clinical questions and triaged topics for systematic review and narrative review. The Work Group and ERT further developed and refined each systematic review topic, specified screening criteria, literature search strategies, and data extraction forms.

The ERT performed literature searches, and conducted abstract and article screening. The ERT also coordinated the methodological and analytic processes of the report. In addition, it defined and standardized the methodology in relation to these searches and data extraction, and produced summaries of the evidence. Throughout the project, the ERT offered suggestions for guideline development, led discussions on systematic review, literature searches, data extraction, assessment of quality and applicability of articles, evidence synthesis, grading of evidence and recommendations, and consensus development. With input from the Work Group, the ERT finalized eligible studies, performed all data extraction, and summarized data into summary tables. They also created preliminary evidence profiles (described below), which were completed by the Work Group members. The Work Group members reviewed all included articles, data extraction forms, and summary tables for accuracy and completeness. The Work Group took the primary role of writing the recommendations and rationale statements, and retained final responsibility for the content of the recommendation statements and the accompanying narrative.

For questions of treatments in GN, systematic reviews of the eligible RCTs were undertaken ([Table 32](#tbl32){ref-type="table"}). For these topics, the ERT created detailed data-extraction forms and extracted information on baseline data for the populations, interventions, study design, results, and provided an assessment of quality of study and outcomes. The ERT then tabulated studies in summary tables, and assigned grades for the quality of the evidence in consultation with the Work Group.

Refinement of Topics
--------------------

At the first 3-day meeting, Work Group members added comments to the scope-of-work document as prepared by the Work Group Chairs and ERT, until the initial working document included all topics of interest to the Work Group. The inclusive, combined set of questions formed the basis for the deliberation and discussion that followed. The Work Group aimed to ensure that all topics deemed clinically relevant and worthy of review were identified and addressed. The major topic areas of interest for the care of GN included IgAN, lupus and vasculitis, MCD and FSGS, and MN, MPGN, and infection.

At the initiation of the guideline development process, it was agreed that these guidelines would focus on patients who have GN. Thus, all topics, systematic reviews, and study eligibility criteria were restricted to patients with a biopsy-proven diagnosis of GN, with exceptions for diseases that do not require biopsy confirmation.

Based on the list of topics, the Work Group and ERT developed a list of specific research questions for which systematic review would be performed. For each systematic review topic, the Work Group Co-Chairs and the ERT formulated well-defined systematic review research questions using a well-established system.^[@bib758]^ For each question, explicit criteria were agreed on for the population, intervention or predictor, comparator, outcomes of interest, and study design features. A list of outcomes of interest was generated.

The Work Group and the ERT agreed upon specific outcomes of interest: all-cause mortality, ESRD, disease remission, relapse, proteinuria, kidney function, and adverse events. ESRD and mortality were ranked as being of critical importance. The Work Group ranked patient-centered clinical outcomes (such as death, ESRD, remission and categorical proteinuria and kidney function changes) as more important than intermediate outcomes (such as continuous outcomes of proteinuria and kidney function). Categorical outcomes are those that describe when a patient moves from one health state (e.g., macroalbuminuria) to another (e.g., no albuminuria). Continuous outcomes would be evaluations of the laboratory values alone (e.g., change in proteinuria in mg/dl). The outcomes were further categorized as being of critical, high, or moderate clinical importance to patients with GN. The specific criteria used for each topic are described below in the description of the review topics. In general, eligibility criteria were determined based on clinical value, relevance to the guidelines and clinical practice, determination whether a set of studies would affect recommendations or the strength of evidence, and practical issues, such as available time and resources.

Literature Searches and Article Selection
-----------------------------------------

Searches were conducted in MEDLINE and Cochrane through January 20, 2011. All searches were also supplemented by articles identified by Work Group members through November 2011. For detailed search strategies, please see Online Appendix 1.

Search results were screened by the ERT for relevance using predefined eligibility criteria, described below. For questions related to treatment, the systematic search aimed to identify RCTs as described in [Table 32](#tbl32){ref-type="table"}. For some topics, nonrandomized comparative trials were also reviewed, in addition to RCTs, to strengthen the evidence base.

For most topics, the minimum sample size was \>10. For MCD and FSGS, because of sparse data, smaller studies were included.

For most topics, the minimum duration of follow-up of 6 months was chosen based on clinical reasoning. For the treatments of interest, the proposed effects on patient-important clinical outcomes require long-term exposure and, typically, would not be expected to become evident before several months of follow-up.

In addition, a search was conducted for data on predictors of kidney failure, kidney function, and remission. Only associations from multivariable regression analyses were considered. These "predictor studies" were not graded for quality. For these topics, the ERT completed its search in October 5, 2009 and did not update the search.

Included were studies of all patients with glomerular diseases, excluding those with diabetic nephropathy, thrombotic microangiopathy, amyloidosis, Alport\'s and other hereditary glomerular diseases, paraproteinemia, and recurrence of GN following kidney transplantation.

Interventions of interest included all treatments for GN, including drugs, herbs, dietary supplements, tonsillectomy, infection prophylaxis, and postdiagnosis tests to determine treatment.

A list of pertinent, published systematic reviews relevant to GN guidelines was generated, organized by topic, and reviewed with the Work Group. If an existing systematic review adequately addressed a question of interest as determined by the Work Group, this was used instead of a *de novo* systematic review by the ERT. These systematic reviews were then used as the starting points for building the evidence base and supplemented with articles from the ERT\'s own searches. If these reviews were deemed to adequately address topics of interest (even if only selected outcomes were reviewed), *de novo* searches on these topics were limited to the time period since the end of literature search within the systematic reviews.

Editorials, letters, stand-alone abstracts, unpublished reports, and articles published in non--peer-reviewed journals were excluded. The Work Group also decided to exclude publications from journal supplements.

### Literature yield for systematic review topics

[Table 33](#tbl33){ref-type="table"} summarizes the numbers of abstracts screened, articles retrieved, studies data extracted, and studies included in summary tables.

### Data extraction

The ERT designed data-extraction forms to tabulate information on various aspects of the primary studies. Data fields for all topics included study setting, patient demographics, eligibility criteria, type of GN, numbers of subjects randomized, study design, study funding source, descriptions of interventions (or predictors), description of outcomes, statistical methods used, results, quality of outcomes (as described below), limitations to generalizability, and free-text fields for comments and assessment of biases.

Summary tables
--------------

Summary tables were developed to tabulate the data from studies pertinent to each question of intervention. Each summary table contains a brief description of the outcome, baseline characteristics of the population, intervention, comparator results, and methodological quality of each outcome. Baseline characteristics include a description of the study size, country of residence, and baseline kidney function and proteinuria. Intervention and concomitant therapies, and the results, were all captured. The studies were listed by outcome within the table, based on the hierarchy of important outcomes ([Table 34](#tbl34){ref-type="table"}). Categorical and continuous outcomes were summarized in separate sets of tables. Work Group members were asked to proof all data in summary tables on RCTs and non-RCTs. Separate sets of summary tables were created for predictor studies. Summary tables are available at [www.kdigo.org/clinical_practice_guidelines/GN.php](http://www.kdigo.org/clinical_practice_guidelines/GN.php).

### Evaluation of individual studies

*Study size and duration:* The study (sample) size is used as a measure of the weight of the evidence. In general, large studies provide more precise estimates. Similarly, longer-duration studies may be of better quality and more applicable, depending on other factors.

*Methodological quality:* Methodological quality (internal validity) refers to the design, conduct, and reporting of the outcomes of a clinical study. A three-level classification of study quality was used ([Table 35](#tbl35){ref-type="table"}). Given the potential differences in quality of a study for its primary and other outcomes, the methodological quality was assessed for each outcome. Variations of this system have been used in most KDOQI and all KDIGO guidelines, and have been recommended for the US Agency for Healthcare Research and Quality Evidence-based Practice Center program ([http://effectivehealthcare.ahrq.gov/repFiles/ 2007_10DraftMethodsGuide.pdf](http://effectivehealthcare.ahrq.gov/repFiles/2007_10DraftMethodsGuide.pdf)). Each study was given an overall quality grade. Each reported outcome was then evaluated and given an individual quality grade depending on reporting and methodological issues specific to that outcome. However, the quality grade of an individual outcome could not exceed the quality grade for the overall study.

*Results:* The results data for each outcome of interest were extracted including baseline values (when relevant), final values (or number of events), and net differences (between interventions). These included net change in values, RR, OR, HR, and risk difference, as reported by the studies. The CI values of the net differences and their statistical significance were also extracted. When necessary, for categorical outcomes, RR and their 95% CI were calculated based on available data. The calculated data were distinguished from the reported data in the summary tables.

### Evidence profiles

Evidence profiles were constructed by the ERT and reviewed and confirmed with the Work Group members. These profiles serve to make transparent to the reader the thinking process of the Work Group in systematically combining evidence and judgments. Each evidence profile was reviewed by Work Group members. Decisions were based on facts and findings from the primary studies listed in corresponding summary tables, as well as selected existing systematic reviews, and judgments of the Work Group. Judgments about the quality, consistency, and directness of evidence were often complex, as were judgments about the importance of an outcome or the summary of effects sizes. The evidence profiles provided a structured transparent approach to grading, rather than a rigorous method of quantitatively summing up grades.

Evidence profiles were constructed for research questions addressed by at least two studies. When the body of evidence for a particular comparison of interest consisted of only one study, either an RCT or a systematic review, the summary table provides the final level of synthesis.

### Grading the quality of evidence and the strength of a recommendation

A structured approach, based on GRADE,^[@bib759],\ [@bib760],\ [@bib761]^ and facilitated by the use of evidence profiles, was used in order to grade the quality of the overall evidence and the strength of recommendations. For each topic, the discussion on grading of the quality of the evidence was led by the ERT, and the discussion regarding the strength of the recommendations was led by the Work Group Co-Chairs. The "strength of a recommendation" indicates the extent to which one can be confident that adherence to the recommendation will do more good than harm. The "quality of a body of evidence" refers to the extent to which our confidence in an estimate of effect is sufficient to support a particular recommendation.^[@bib760]^

*Grading the quality of evidence for each outcome:* Following the GRADE method, the quality of a body of evidence pertaining to a particular outcome of interest was initially categorized based on study design. For questions of interventions, the initial quality grade was "High" when the body of evidence consisted of RCTs. In theory, the initial grade would have been "Low" if the evidence consisted of observational studies or "Very Low" if it consisted of studies of other study designs; however, the quality of bodies of evidence was formally determined only for topics where we performed systematic reviews of RCTs. The grade for the quality of evidence for each intervention/outcome pair was decreased if there were serious limitations to the methodological quality of the aggregate of studies, if there were important inconsistencies in the results across studies, if there was uncertainty about the directness of evidence including limited applicability of the findings to the population of interest, if the data were imprecise (a low event rate \[0 or 1 event\] in either arm or CI spanning a range \<0.5 to \>2.0) or sparse (only one study or total *N*\<100), or if there was thought to be a high likelihood of bias. The final grade for the quality of the evidence for an intervention/outcome pair could be one of the following four grades: "High", "Moderate", "Low", or "Very Low" ([Table 36](#tbl36){ref-type="table"}). The quality of grading for topics relying on systematic reviews are based on quality items recorded in the systematic review.

*Grading the overall quality of evidence:* The quality of the overall body of evidence was then determined based on the quality grades for all outcomes of interest, taking into account explicit judgments about the relative importance of each outcome, weighting critical outcomes more than high or moderate. The resulting four final categories for the quality of overall evidence were: "A", "B", "C" or "D" ([Table 37](#tbl37){ref-type="table"}). This evidence grade is indicated within each recommendation.

*Assessment of the net health benefit across all important clinical outcomes:* The net health benefit was determined based on the anticipated balance of benefits and harm across all clinically important outcomes. The assessment of net medical benefit was affected by the judgment of the Work Group. The assessment of net health benefit is summarized in [Table 38](#tbl38){ref-type="table"}.

*Grading the strength of the recommendations:* The strength of a recommendation is graded as Level 1 or Level 2. [Table 39](#tbl39){ref-type="table"} shows the KDIGO nomenclature for grading the strength of a recommendation, and the implications of each level for patients, clinicians, and policy-makers. Recommendations can be for or against doing something. [Table 40](#tbl40){ref-type="table"} shows that the strength of a recommendation is determined not just by the quality of the evidence, but also by other---often complex---judgments regarding the size of the net medical benefit, values, and preferences, and costs. Formal decision analyses including cost analysis were not conducted.

*Ungraded statements:* This category was designed to allow the Work Group to issue general advice. Typically an ungraded statement meets the following criteria: it provides guidance based on common sense; it provides reminders of the obvious; it is not sufficiently specific to allow application of evidence to the issue and, therefore, it is not based on systematic evidence review. Common examples include recommendations about frequency of testing, referral to specialists, and routine medical care. We strove to minimize the use of ungraded recommendations.

This grading scheme with two levels for the strength of a recommendation together with four levels of grading the quality of the evidence, and the option of an ungraded statement for general guidance, was adopted by the KDIGO Board in December 2008. The Work Group took the primary role of writing the recommendations and rationale statements, and retained final responsibility for the content of the guideline statements and the accompanying narrative. The ERT reviewed draft recommendations and grades for consistency with the conclusions of the evidence review.

### Format for recommendations

Each section contains one or more specific recommendations. Within each recommendation, the strength of recommendation is indicated as level 1 or level 2, and the quality of the supporting evidence is shown as A, B, C, or D. These are followed by a brief background with relevant definitions of terms, then the rationale starting with a "chain of logic", which consists of declarative sentences summarizing the key points of the evidence base, and the judgments supporting the recommendation. This is followed by a narrative in support of the rationale. In relevant sections, research recommendations suggest future research to resolve current uncertainties.

Limitations of Approach
-----------------------

While the literature searches were intended to be comprehensive, they were not exhaustive. MEDLINE and various Cochrane databases were the only databases searched. Hand searches of journals were not performed, and review articles and textbook chapters were not systematically searched. However, important studies known to the domain experts that were missed by the electronic literature searches were added to retrieved articles and reviewed by the Work Group. Not all topics and subtopics covered by these guidelines could be systematically reviewed. Decisions to restrict the topics were made to focus the systematic reviews on those topics where existing evidence was thought to be likely to provide support for the guidelines. Although nonrandomized studies were reviewed, the majority of the ERT and Work Group resources were devoted to review of the randomized trials, since these were deemed to be most likely to provide data to support level 1 recommendations with very high- or high- (A or B) quality evidence. Where randomized trials were lacking, it was deemed to be sufficiently unlikely that studies previously unknown to the Work Group would result in higher-quality level 1 recommendations.

Review of the Guideline Development Process
-------------------------------------------

Several tools and checklists have been developed to assess the quality of the methodological process for systematic review and guideline development. These include the Appraisal of Guidelines for Research and Evaluation (AGREE) criteria,^[@bib762]^ the Conference on Guideline Standardization (COGS) checklist,^[@bib763]^ and and the Institute of Medicine\'s recent *Standards for Systematic Reviews*^[@bib764]^ and *Clinical Practice Guidelines We Can Trust*.^[@bib765]^ Online Appendices 2 and 3 show the COGS criteria that correspond to the AGREE checklist and the Institute of Medicine standards, and how each one of them is addressed in this guideline.

**SUPPLEMENTARY MATERIAL**

*Appendix 1:* Online search strategies.

*Appendix 2:* The Conference on Guideline Standardization (COGS) checklist for reporting clinical practice guidelines.

*Appendix 3:* Concurrence with Institute of Medicine standards for systematic reviews and for guidelines.

Supplementary material is linked to the online version of the paper at <http://www.kdigo.org/clinical_practice_guidelines/GN.php>

###### Screening criteria for systematic review topics of nontreatment and treatment
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###### Literature search yield of RCTs

  **Topic**    **Abstracts identified[a](#t33-fn2){ref-type="fn"}**   **Studies retrieved**   **Studies data-extracted**   **No. of systematic reviews**   **No. of summary tables[b](#t33-fn3){ref-type="fn"}**   **No. of evidence profiles[b](#t33-fn3){ref-type="fn"}**
  ----------- ------------------------------------------------------ ----------------------- ---------------------------- ------------------------------- ------------------------------------------------------- ----------------------------------------------------------
  Total                               13,516                                   418                        94                            12                                          72                                                        18

RCTs, randomized controlled trials.

All topics and all study designs combined.

Available at: [www.kdigo.org/clinical_practice_guidelines/GN.php](http://www.kdigo.org/clinical_practice_guidelines/GN.php).

###### Hierarchy of outcomes
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###### Classification of study quality
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###### GRADE system for grading quality of evidence

  **Step 1: Starting grade for quality of evidence based on study design**   **Step 2: Reduce grade**                                                                                                       **Step 3: Raise grade**                                                                                                                                                                 **Final grade for quality of evidence and definition**
  -------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Randomized trials=High                                                     *Study quality* --1 level if serious limitations --2 levels if very serious limitations                                        *Strength of association* +1 level if strong[a](#t36-fn2){ref-type="fn"}, no plausible confounders +2 levels if very strong[b](#t36-fn3){ref-type="fn"}, no major threats to validity   High=Further research is unlikely to change confidence in the estimate of the effect
                                                                                                                                                                                                                                                                                                                                                                                                     
  Observational study=Low                                                    *Consistency* --1 level if important inconsistency*Directness* --1 level if some uncertainty --2 levels if major uncertainty   *Other* +1 level if evidence of a dose-response gradient +1 level if all residual plausible confounders would have reduced the observed effect                                          Moderate=Further research is likely to have an important impact on confidence in the estimate of effect, and may change the estimate Low=Further research is very likely to have an important impact on confidence in the estimate, and may change the estimate
                                                                                                                                                                                                                                                                                                                                                                                                     
  Any other evidence=Very Low                                                *Other* --1 level if sparse or imprecise data[c](#t36-fn4){ref-type="fn"} --1 level if high probability of reporting bias                                                                                                                                                                                              Very Low=Any estimate of effect is very uncertain

GRADE, Grading of Recommendations Assessment, Development, and Evaluation.

Strong evidence of association is defined as "significant relative risk of \>2 (\<0.5)" based on consistent evidence from two or more observational studies, with no plausible confounders.

Very strong evidence of association is defined as "significant relative risk of \>5 (\<0.2)" based on direct evidence with no major threats to validity.

Sparse if there is only one study or if total N \<100. Imprecise if there is a low event rate (0 or 1 event) in either arm or confidence interval spanning a range \<0.5 to \>2.0.

Adapted by permission from Macmillan Publishers Ltd: Kidney International. Uhlig K, Macleod A, Craig J *et al.* Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2006; 70: 2058--2065^[@bib761]^; accessed [http://www.nature.com/ki/journal/v70/n12/ pdf/5001875a.pdf](http://www.nature.com/ki/journal/v70/n12/pdf/5001875a.pdf).

###### Final grade for overall quality of evidence
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###### Balance of benefits and harm

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  When there was evidence to determine the balance of medical benefits and harm of an intervention to a patient, conclusions were categorized as follows:
   • **Net benefits=**the intervention clearly does more good than harm
   • **Trade-offs=**there are important trade-offs between the benefits and harm
   • **Uncertain trade-offs=**it is not clear whether the intervention does more good than harm
   • **No net benefits=**the intervention clearly does not do more good than harm
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

###### KDIGO nomenclature and description for grading recommendations

  **Grade[a](#t39-fn1){ref-type="fn"}**   **Implications**                                                                                                                                                                                                                                                                                 
  --------------------------------------- ------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------
  **Level 1** "We recommend"              Most people in your situation would want the recommended course of action and only a small proportion would not.   Most patients should receive the recommended course of action.                                                                                                                The recommendation can be evaluated as a candidate for developing a policy or a performance measure.
                                                                                                                                                                                                                                                                                                                                            
  **Level 2** "We suggest"                The majority of people in your situation would want the recommended course of action, but many would not.          Different choices will be appropriate for different patients. Each patient needs help to arrive at a management decision consistent with her or his values and preferences.   The recommendation is likely to require substantial debate and involvement of stakeholders before policy can be determined.

The additional category "Not Graded" was used, typically, to provide guidance based on common sense or where the topic does not allow adequate application of evidence. The most common examples include recommendations regarding monitoring intervals, counseling, and referral to other clinical specialists. The ungraded recommendations are generally written as simple declarative statements, but are not meant to be interpreted as being stronger recommendations than Level 1 or 2 recommendations.

###### Determinants of strength of recommendation
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